MedTrace Logo

Trial for Hepatocellular Carcinoma Adjuvant Treatment by Lipiocis

NCT00116454 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 73

Last updated 2026-04-03

No results posted yet for this study

Summary

The recurrence of hepatocellular carcinoma (HCC), two years after curative treatment is high, about 40% - 50%. Recently, it has been shown that intra-arterial radioactive lipiodol (Lipiocis®) could reduce the recurrence of cancer and increase the survival after resection of HCC developed on cirrhosis B. The aim of the present trial is to investigate the effect of Lipiocis® in preventing recurrence after curative treatment of HCC in patients with viral or alcoholic hepatitis related cirrhosis by surgical or percutaneous ablation.

Conditions

  • Carcinoma, Hepatocellular
  • Hepatitis, Viral, Human

Interventions

DRUG

131 I-lipiodol

intra-arterial hepatic administration of Lipiocis will occur, 11 to 12 weeks after the initial curative treatment

Sponsors & Collaborators

  • ANRS, Emerging Infectious Diseases

    lead OTHER_GOV

Principal Investigators

  • Olivier Rosmorduc, MD · Hopital Saint Antoine SERVICE D'HEPATOLOGIE

  • Fabrice Carrat, MD · INSERM U 444 FACULTE DE MEDECINE ST ANTOINE

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-07-31
Primary Completion
2013-08-31
Completion
2013-08-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00116454 on ClinicalTrials.gov